| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/22/2012 | CA2371977C Media in the form of complex dispersions, their process of preparation and their uses |
| 05/18/2012 | WO2012065060A2 Gas-filled microbubbles and systems for gas delivery |
| 05/18/2012 | WO2012064824A1 Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| 05/18/2012 | WO2012064766A2 Sheet and liquid combination systems for dermal drug delivery |
| 05/18/2012 | WO2012064429A2 Skin permeating and cell entering (space) peptides and methods of use thereof |
| 05/18/2012 | WO2012064377A1 Antifolate compositions |
| 05/18/2012 | WO2012064307A1 Pharmaceutical compositions comprising rosuvastatin |
| 05/18/2012 | WO2012064306A2 Effervescent formulations of rosuvastatin |
| 05/18/2012 | WO2012064305A2 Formulations with improved physical characteristics |
| 05/18/2012 | WO2012064304A2 Combinations comprising montelukast |
| 05/18/2012 | WO2012064303A2 Improved montelukast combinations |
| 05/18/2012 | WO2012064302A2 Improved montelukast formulations |
| 05/18/2012 | WO2012064301A2 Physically improved tablet formulations |
| 05/18/2012 | WO2012064267A1 A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| 05/18/2012 | WO2012064088A2 Pharmaceutical composition including polymer microsphere containing olanzapine as active ingredient |
| 05/18/2012 | WO2012064087A2 Pharmaceutical composition including polymer microsphere containing anastrozole as active ingredient |
| 05/18/2012 | WO2012063947A1 Gel sheet comprising lipidic peptide type gelling agent and polymeric compound |
| 05/18/2012 | WO2012063870A1 Stem cell suspension |
| 05/18/2012 | WO2012063509A1 Amphipathic liquid crystal compound, micelle, and use of the compound or the micelle |
| 05/18/2012 | WO2012063498A2 Novel exemestane solid dispersion |
| 05/18/2012 | WO2012063005A2 Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof |
| 05/18/2012 | WO2012062835A1 Novel pharmaceutical compositions |
| 05/18/2012 | WO2012062834A1 Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| 05/18/2012 | WO2012062691A1 Pharmaceutical compositions for treating hcv infections |
| 05/18/2012 | WO2012062685A2 Pharmaceutical composition for treating hcv infections |
| 05/18/2012 | WO2012062676A1 Lisuride, terguride and derivatives thereof for use in the prophylaxis and/or treatment of fibrotic changes |
| 05/18/2012 | WO2012062360A1 Polymeric bone foam composition and method |
| 05/18/2012 | WO2012061902A1 Micronised spray-dried particles comprising polymyxin |
| 05/18/2012 | WO2012040651A3 Controlled release formulations of opioids |
| 05/18/2012 | WO2012040228A3 Aerosol composition for administering drugs |
| 05/18/2012 | WO2012039691A3 Synergic effect between n- acetylcysteine and a third generation h1 antagonist such as levoceterizine and desloratadine |
| 05/18/2012 | WO2012034079A3 Macrolide dosage forms |
| 05/18/2012 | WO2012027711A3 Compositions and methods for treating bone defects |
| 05/18/2012 | WO2012021715A3 Stable formulations of linaclotide |
| 05/18/2012 | WO2012016229A3 Oxytocin treatment to improve memory and modify blood glucose |
| 05/18/2012 | WO2012015979A3 Hmgb1-derived peptides enhance immune response to antigens |
| 05/18/2012 | WO2012010944A3 Multiple unit tablet composition |
| 05/18/2012 | WO2012008718A3 Patch for treating and alleviating symptoms of skin diseases accompanied by effusion of blood proteins |
| 05/18/2012 | WO2012001494A3 Pharmaceutical compositions comprising paracetamol and process for preparing the same |
| 05/18/2012 | WO2011161531A9 Pharmaceutical composition containing goserelin for in-situ implant |
| 05/18/2012 | WO2011154975A3 Pharmaceutical compositions of metformin |
| 05/18/2012 | WO2011146684A3 Nano-scale coatings and related methods suitable for in-vivo use |
| 05/18/2012 | WO2011139256A3 Stable rosuvastatin formulations |
| 05/18/2012 | WO2011137877A3 A pharmaceutical composition containing solifenacin and a method of its manufacture |
| 05/18/2012 | WO2011128629A3 Lipid-vectored drug compositions |
| 05/18/2012 | WO2011128625A3 Divisible oral pharmaceutical compositions |
| 05/18/2012 | WO2011110930A3 Rifaximin ready-to-use suspension |
| 05/18/2012 | WO2011095269A3 Directly compressible magnesium hydroxide carbonate |
| 05/18/2012 | WO2011091225A3 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
| 05/18/2012 | WO2011049629A9 Methods of making and using compositions comprising flavonoids |
| 05/18/2012 | WO2010062688A3 Dosage form for insertion into the mouth |
| 05/18/2012 | WO2009152483A3 Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma |
| 05/18/2012 | CA2834882A1 Lisuride, terguride and derivatives thereof for use in the prophylaxis and/or treatment of fibrotic changes |
| 05/18/2012 | CA2817755A1 Modified immune-modulating particles |
| 05/18/2012 | CA2817547A1 Sheet and liquid combination systems for dermal drug delivery |
| 05/18/2012 | CA2817310A1 Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof |
| 05/18/2012 | CA2817172A1 Stem cell suspension |
| 05/18/2012 | CA2815698A1 A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| 05/18/2012 | CA2815689A1 Improved high concentration anti-tnf.alpha. antibody liquid formulations |
| 05/18/2012 | CA2813851A1 Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| 05/18/2012 | CA2812665A1 Pharmaceutical composition for treating hcv infections |
| 05/18/2012 | CA2811113A1 Skin permeating and cell entering (space) peptides and methods of use thereof |
| 05/17/2012 | US20120123355 Erodible embolization material |
| 05/17/2012 | US20120123182 Devices for thermally induced transformations controlled by irradiation of functionalized fullerenes |
| 05/17/2012 | US20120122973 Dry processing of retigabine |
| 05/17/2012 | US20120122829 Pharmaceutical composition for transdermal or transmucous administration |
| 05/17/2012 | US20120122694 Verbesserte microkapseln und ihre herstellung improved microcapsules, and their production thereof |
| 05/17/2012 | US20120122691 Cellulosic biocomposites as molecular scaffolds for nano-architectures |
| 05/17/2012 | US20120121774 System and method for coating bulk articles |
| 05/17/2012 | US20120121724 Film comprising therapeutic agents |
| 05/17/2012 | US20120121718 Compositions and methods relating to reduced mucoadhesion |
| 05/17/2012 | US20120121717 DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD |
| 05/17/2012 | US20120121716 Pharmaceutical composition of an anthracycline |
| 05/17/2012 | US20120121715 DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof |
| 05/17/2012 | US20120121714 Compositions with antigens adsorbed to calcium phosphate |
| 05/17/2012 | US20120121713 Chimeric therapeutics, compositions, and methods for using same |
| 05/17/2012 | US20120121712 Cellular electric stimulation mediated by piezoelectric nanotubes |
| 05/17/2012 | US20120121711 Microsphere drug carrier, preparation method, composition and use thereof |
| 05/17/2012 | US20120121710 Mucosal Immunization |
| 05/17/2012 | US20120121709 Phase transition biopolymers and methods of use |
| 05/17/2012 | US20120121708 Acetazolamide Microparticle And Its Preparation Method And Use |
| 05/17/2012 | US20120121707 Tolbutamide Particle And Preparing Method Thereof And Method Of Reducing A Blood Glucose |
| 05/17/2012 | US20120121706 PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
| 05/17/2012 | US20120121704 Aliphatic Amine Polymer Salts for Tableting |
| 05/17/2012 | US20120121703 Tablet containing ferric citrate |
| 05/17/2012 | US20120121702 Controlled Release Azithromycin Solid Dosage Forms |
| 05/17/2012 | US20120121701 Pharmaceutical composition of peptide drug and enzyme-inhibition compounds |
| 05/17/2012 | US20120121700 Pharmaceutical formulations comprising valganciclovir |
| 05/17/2012 | US20120121699 Lycopene and resveratrol dietary supplement |
| 05/17/2012 | US20120121698 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| 05/17/2012 | US20120121697 Compositions and Methods for the Diagnosis and Treatment of Inflammatory Disorders and Fibrotic Disease |
| 05/17/2012 | US20120121696 Terpene Glycosides and Their Combinations as Solubilizing Agents |
| 05/17/2012 | US20120121695 Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine |
| 05/17/2012 | US20120121694 Compositions and Kits for Ocular Treatment |
| 05/17/2012 | US20120121693 Methods for generating new hair follicles, treating baldness, and hair removal |
| 05/17/2012 | US20120121692 Compounds and compositions comprising cdk inhibitors and methods for treating cancer |
| 05/17/2012 | US20120121691 Method for Increasing the Production of a Specific ACYL-Chain Dihydroceramide(s) for Improving the Effectiveness of Cancer Treatments |
| 05/17/2012 | US20120121690 Method to enhance an immune response of nucleic acid vaccination |
| 05/17/2012 | US20120121689 Small interfering rna delivery |
| 05/17/2012 | US20120121688 Preventative or therapeutic agent and method for immune disease |